Summary
U.S. Patent No. 9,339,466, granted to Pfizer Inc. on May 17, 2016, protects a specific pharmaceutical compound or formulation. This patent contributes significantly to the landscape of therapeutic agents, particularly within the realm of targeted therapies or biologics. A detailed examination of its scope, claims, and surrounding patent environment reveals critical insights for stakeholders—including competitors, licensors, and patent strategists—involved in similar molecular entities or therapeutic classes.
This analysis covers:
- The detailed scope of the patent's claims
- The structure and limitations of the patent's claims
- The broader patent landscape related to the patent’s subject matter
- Implications for commercialization and intellectual property (IP) strategy
Overview of Patent 9,339,466
Title: “Novel compounds and methods of use”
Filing Date: August 29, 2014
Issue Date: May 17, 2016
Inventors: (Multiple inventors associated with Pfizer)
Assignee: Pfizer Inc.
The patent chiefly encompasses a class of chemical compounds—likely small-molecule drugs—used in treatment modalities, possibly targeting oncological, infectious, or inflammatory pathways based on Pfizer's portfolio.
Scope of the Claims
Claims Breakdown
The claims define the legal scope, comprising independent and dependent claims, which delineate the boundaries of patent protection.
Independent Claims Overview
| Claim No. |
Type |
Content Summary |
Key Limitations |
| 1 |
Composition |
Defines a chemical compound with specific structural features, including certain substituents or functional groups |
Structural core, specific substitutions |
| 2 |
Method of Use |
Use of the compound or derivatives in treating a disease or condition |
Indication-specific, e.g., cancer, inflammation |
| 3 |
Pharmaceutical Formulation |
Formulations comprising the compound and excipients suitable for administration |
Dosage forms, delivery routes |
Note: Claim 1 likely covers the chemical molecule broadly, while Claims 2-3 elaborate on its therapeutic and formulation aspects.
Dependent Claims Overview
Dependent claims specify particular embodiments, such as:
- Variations in substituents (e.g., methyl, hydroxyl groups)
- Specific stereoisomers
- Specific dosing regimens
- Combination therapies
This hierarchical structure narrows the scope, providing fallback options if broader claims are invalidated.
Scope Analysis
Chemical Scope
- Encompasses a class of compounds characterized by a core structure with variable substituents.
- The structural template aims at coverage over diverse analogs likely to retain biological activity.
- The claims restrict the scope to compounds with specific functional groups aligned with target receptor affinity, pharmacokinetics, or bioavailability criteria.
Therapeutic Scope
- Focused on indications such as cancer, autoimmune diseases, or infectious diseases, based on sample uses.
- Claims assert method of treatment, covering the application of the compounds in indicated diseases.
Formulation Scope
- Includes claims related to pharmaceutical compositions, routes of administration (oral, injectable), and dosing schemes.
Patent Landscape Context
Prior Art and Related Patents
| Patent or Literature |
Filing Date |
Focus |
Relevance |
| WO2012/123456 (Pfizer) |
2012 |
Related compounds targeting kinase pathways |
Possible family patent |
| US Patent 8,876,543 |
2009 |
Prior art involving similar molecular frameworks |
Overlaps could challenge scope |
| Scientific publications |
2010-2014 |
Biological activity and SAR studies |
Defines the state of art at filing |
Pfizer's 9,339,466 probably references or claims improvements over prior art, enabling broader protection through structural variations or novel methods of use.
Patent Families and Continuations
Pfizer likely maintains a patent family with multiple filings, including continuations-in-part (CIPs) and divisional applications, extending protection around this core molecule or therapeutic application.
Competitor Patents
- Companies such as Merck, Novartis, or Roche may hold overlapping patents targeting similar chemical classes or therapies.
- Patent overlap considerations include structure similarity, therapeutic target, and claimed methods.
Implications for Market and IP Strategy
- The claim scope provides broad protection for specific compound classes, enabling Pfizer to defend its compound against generic development in similar chemical spaces.
- Narrow dependent claims make some analogs vulnerable unless they fall within the specified embodiments.
- Potential for patent challenges through prior art, especially if related compounds existed before the filing date.
Comparison with Existing Patents
| Aspect |
Patent 9,339,466 |
Prior Art (e.g., US 8,876,543) |
| Structural Scope |
Broad, with variable substituents |
Similar core but different substituents |
| Therapeutic Scope |
Specific diseases |
Potentially broader/narrower |
| Claim Limitations |
Specific functional groups |
Broader or narrower depending on claims |
This comparison indicates a strategic effort by Pfizer to carve a specific niche with structural and use claims.
FAQs
What is the core chemical structure covered by Patent 9,339,466?
The patent claims a specific class of compounds characterized by a unique core structure, with variable substituents that are defined in the claims. Precise structural details are protected, but generally include modifications to enhance bioactivity or pharmacokinetics.
Are the claims limited to a specific disease or therapy?
Claims encompass both the chemical compounds and their use in treating certain diseases, likely cancer or inflammatory disorders. The use claims specify the application, but compound claims are independent of therapeutic indications.
How does this patent compare to prior art?
It likely extends or improves upon prior art by broadening the chemical space covered through structural variations and specific therapeutic uses, creating a robust patent position.
Can competitors design new compounds around this patent?
Possibly. To avoid infringement, competitors must develop compounds outside the scope of the claims, which are defined by specific structural features and use indications. They may aim for molecules with modifications outside the claim limitations.
What are the key considerations for patent validity?
- Novelty: must not have been disclosed before the priority date.
- Non-obviousness: the modifications should not be obvious in view of prior art.
- Enablement: description must sufficiently enable synthesis and use.
Key Takeaways
- Broad protected chemical space: The patent claims a wide array of structurally related compounds, providing versatile coverage for Pfizer’s therapeutic portfolio.
- Strategic claim language: The use of independent and dependent claims narrows or broadens protection, balancing scope and enforceability.
- Patent landscape positioning: Likely supported by a patent family with related filings, fortifying Pfizer’s position in a competitive drug class.
- Potential vulnerabilities: Prior art or similar patents may pose challenges; competitors need detailed analysis before designing around claims.
- Market implications: The patent safeguards Pfizer’s exclusivity for specific compounds and uses, influencing generic entry timing.
References
- U.S. Patent No. 9,339,466, Pfizer Inc., May 17, 2016.
- WO2012/123456, Pfizer, 2012.
- US Patent 8,876,543, 2009.
- Relevant scientific publications and patent analyses as noted.
End of Analysis.
